In recent years, various studies have confirmed the predictive power of the AIP, as a marker of plasma atherogenicity, in MetS, atherosclerosis, diabetes, and non-alcoholic fatty liver disease [36–38]. The gene discussed is AIP; the disease is metabolic dysfunction-associated steatotic liver disease.